Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BR1019 FDC vs Co-administered Fimasartan and Dapagliflozin in Healthy Volunteers
NCT06226727Phase 1Completed
- Sponsor
- Boryung
- Start
- Feb 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fimasartan and dapagliflozin in type 2 diabetes mellitus (T2DM) and essential hypertension (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Concentration-Time Curve over the Dosing Interval and Maximum Plasma Concentration. Started Feb 2024; status: completed.
02
Drugs
fimasartandapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)essential hypertension
Beyond the preview
Go deeper on NCT06226727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226727.